Evidence map›Paper›PMID 42769123›Full record

ArticleDrug design, development and therapy2026

Structural Prerequisites for Pim-1 Kinase Inhibition and the Identification of a Pyrazolyl-Methylene-Indolinone Hit.

Rufaida Al Zoubi, Omar Hadieh, Soraya Alnabulsi, Israa H Isawi, Shubin Liu

Abstract read
In one paragraph

Article in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Rufaida Al ZoubiDepartment of Medicinal Chemistry and Pharmacognosy, Faculty of Pharmacy, Jordan University of Science and Technology, Irbid, Jordan.ORCID 0000-0001-8417-4769
Omar HadiehDepartment of Medicinal Chemistry and Pharmacognosy, Faculty of Pharmacy, Jordan University of Science and Technology, Irbid, Jordan.ORCID 0009-0000-2375-0419
Soraya AlnabulsiDepartment of Medicinal Chemistry and Pharmacognosy, Faculty of Pharmacy, Jordan University of Science and Technology, Irbid, Jordan.
Israa H IsawiDepartment of Medicinal Chemistry and Pharmacognosy, Faculty of Pharmacy, Jordan University of Science and Technology, Irbid, Jordan.ORCID 0000-0002-4342-5370
Shubin LiuResearch Computing Center, University of North Carolina, Chapel Hill, NC, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Pim-1 is a serine/threonine kinase of the pan-Pim family (Pim-1, -2, and -3), whose overexpression is associated with various cancers. Its distinctive hinge-region architecture provides opportunities for selective inhibitor development, with several inhibitors reported as clinical candidates. Understanding structure-activity relationships is essential for distinguishing biologically active compounds from high-scoring docking hits, a major challenge in structure-based drug discovery. Methods: A virtual screening workflow comprising Glide docking and Induced Fit Docking (IFD) was applied to approximately 900,000 commercially available compounds. Six structurally diverse compounds were selected for in vitro Pim-1 inhibitory activity evaluation. Molecular dynamics (MD) simulations and quantum mechanical (QM) calculations were subsequently performed to investigate the structural determinants of inhibitory activity. Results: Among the tested compounds, compound Discussion: These findings provide insight into the structural and conformational requirements for productive Pim-1 inhibition and highlight the value of integrating docking, MD simulations, and QM calculations during the search for novel inhibitors. The identified hit represents a previously unreported scaffold for Pim-1 inhibition that may provide a starting point for future optimization.

Indexed as

IndolesProtein Kinase InhibitorsProto-Oncogene Proteins c-pim-1PyrazolesDose-Response Relationship, DrugHumansMolecular Docking SimulationMolecular Dynamics SimulationMolecular StructureStructure-Activity RelationshipIndolesPIM1 protein, humanProtein Kinase InhibitorsProto-Oncogene Proteins c-pim-1Pyrazoles1H-pyrazolyl-methylene-indolinonemolecular dynamics simulationpim-1 kinasequantum mechanical calculationsstructure-activity relationshipvirtual screening

Identifiers

PMID42769123
PMCPMC13590258

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.